Year: 2025
Type: article
Abstract: Alzheimer Disease is the number-one source of cognitive deterioration across the globe and therapeutic advancements intreating this disease are largely limited by both the defense and limitation protecting the brain by the Blood-Brain Barrier(BBB). The fact that conventional drugs are not able to penetrate the BBB has led to the development of superior deliverysystems. Strategies involving nanoparticles have become a solution of prospect, as they offer better permeability, targeteddelivery and increased therapeutic efficacy. This research gives the systematic discussion of nanoparticle methods aimed atconquering the BBB hurdle in the management of the disease of Alzheimer.The review summarizes the recent progress in nanoparticle design, such as polymeric, lipid-based, metallic, and biomimeticsystems, focusing on how they carry their cargo such as receptor-mediated transcytosis, and adsorptive-mediated transportation.Strategies involving functionalization of the conjugates are under discussion (ligand conjugation, PEGylation, and changes insurface charges) and play a critical role in enhancing targeting specificity and systemic stability. Other delivery methods suchas intranasal delivery are also considered on account of their ability to circumvent the BBB limitations.Recent research indicates that nanoparticle-mediated delivery systems can be used to increase the bioavailability of drugs, helpclear the amyloid-beta, regulate neuroinflammation, and deliver gene-based therapies. Moreover, theranostic nanoparticlescombining diagnostic imaging with therapeutic medicinal properties are also a major breakthrough in precision medicine.Regardless of these encouraging progress, issues of toxicity, mass production, and regulatory acceptance still exist.On balance, nanoparticle strategies can be discussed as a revolutionary way out of the BBB-related limitations, and theopportunity to find new ways of effective treatment of Alzheimer disease. More innovation and research in nanoparticleengineering and translational research should continue to close the gap between experimental achievement and clinical use.
Author: Grace, Arogundade Toluwalope
Institution: Northeastern University
Language: English
Subfield: Biomaterials
Field: Materials Science
Domain: Physical Sciences
Keywords: Alzheimer's disease, blood-brain barrier, nanoparticle drug delivery, polymeric nanoparticles, lipid nanoparticles, metal nanoparticles, biomimetic nanoparticles, receptor-mediated transcytosis, PEGylation, ligand conjugation, surface charge, intranasal drug delivery, amyloid-beta clearance, neuroinflammation, gene therapy delivery, theranostic nanoparticles, drug bioavailability
Open Access status: diamond
OpenAlex ID: W7223711518
